Herpes Zoster Market Highlights:

One of the most distressing complications arising from herpes zoster is Postherpetic Neuralgia (PHN), a chronic pain condition that can persist long after the rash subsides. As a key player in the Herpes Zoster Market, addressing the burden of PHN remains a top priority for healthcare providers and pharmaceutical companies alike. Postherpetic Neuralgia casts a shadow over the lives of those affected, disrupting daily activities and diminishing quality of life. Amidst this challenge, innovative therapies targeting PHN are on the rise, offering relief to individuals plagued by persistent pain. As research endeavors continue to unravel the intricacies of neuropathic pain mechanisms, the Herpes Zoster Market holds promise for delivering transformative solutions that alleviate the suffering associated with Postherpetic Neuralgia.

Herpes Zoster Market insights report has valued the industry size at USD 0.15 billion in 2022 and is projected to grow from USD 0.16 Billion in 2023 to USD 0.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.90% during the forecast period (2023 - 2030).

Segmentation:

The global herpes zoster market is segmented into Diagnosis, application, end-users. The herpes zoster market, by Diagnosis, the market is segmented into laboratory testing and others. The laboratory testing segment is further categorized into immunofluorescent microscopy, real-time Polymerase Chain Reaction (PCR), serological testing. The treatment and prevention segment for the global herpes zoster market is divided into antiviral medications, narcotic medications, anti-inflammatory medications, antihistamines, anticonvulsants, capsaicin, numbing creams, gels, or patches, vaccines, and others. The route of administration segment for the global herpes zoster market is divided into oral, topical, and others. The end-user segment for the global herpes zoster market is divided into hospitals & clinics, diagnostic centers, research & academic institutes, home care settings, and others.

Regional Analysis:

The Americas is the largest in the market owing to the increasing government support for vaccination and the highly advanced healthcare facilities to address the growing incidence of the infection. The number of Americans aged 65 or above are projected to be doubled from 46 million to 98 million by 2060, with the subsequent rise in the older age group to nearly 24 percent of the total population from the present 15 percent. The disease is prevalent in older adults usually between 60 -80 years due to the weak immune system thereby providing an opportunity for future growth of the market.

European region is the second largest market over the forecast period due to factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster will provide considerable growth opportunities to herpes zoster treatment companies in the European region. The growing prevalence of the herpes zoster infection in the regions such as Asia Pacific and Middle East & Africa which will emerge as the fastest growing regions in the global herpes zoster infection treatment market.

Key Players:

Some of the key players in the herpes zoster market outlook report are Astellas Pharma Inc. (Japan), Foamix Pharmaceuticals (Israel), Geneone Life Science (South Korea), GlaxoSmithKline plc (UK), Merck & Co. Inc. (US), NAL Pharma (Hong Kong), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), TSRL, Inc. and others.

For more information visit at MarketResearchFuture